CPHI & PMEC India splits across two venues in November 2026
CPHI and PMEC, India’s largest pharma exhibitions will run across Delhi and Greater Noida in November because registrations outgrew any single venue.
After registrations outgrow a single site
CPHI & PMEC India will run across two venues for the first time this November because registrations had outgrown any single site, Informa Markets in India said at a media briefing in Hyderabad on 13 August 2026.
CPHI India, covering finished dosage, excipients, natural extracts, fine chemicals, intermediates and active pharmaceutical ingredients, runs from 23 to 25 November at IICC Yashobhoomi, Dwarka. PMEC India, covering cleanroom technology, machinery and equipment, packaging, and laboratory and analytical equipment, runs from 24 to 26 November at IEML, Greater Noida. The two shows overlap on 24 and 25 November.
The organisers said an updated event app will help visitors plan which halls to attend across the overlap, and that shuttle services will run between the two venues on the overlapping days. A single registration covers both shows.
The 19th edition is expected to draw about 50,000 participants, in line with the 2025 edition, which was held at a single venue in Greater Noida with more than 2,000 exhibitors. Informa said it expects visitors from over 120 countries including Canada, Brazil, Argentina, Switzerland and Bangladesh, and that it also expects US participation despite the tariff measures now applying to pharmaceutical products, though the full effect would only become clear closer to the show.
The Hyderabad briefing was staged to place South India’s priorities in the build-up to the November editions. Rahul Deshpande, senior group director at Informa Markets in India, said Hyderabad and Telangana occupy “a distinctive position within India’s pharmaceutical landscape”, citing the state’s share of national pharmaceutical output and of global vaccine production, and said collaboration across manufacturers, contract manufacturers, ingredient suppliers and technology providers would matter more as companies invest in complex manufacturing and stronger compliance.
Telangana’s Next-Gen Life Sciences Policy 2026-30 counts more than 2,000 life sciences companies and over 250 USFDA-approved manufacturing sites in the state, and targets USD 25 billion in investment and five lakh jobs over the policy period.
The organisers also pointed to India’s contract research, development and manufacturing industry, which they put at around USD 14 billion by 2028 and up to USD 22 billion by 2030, and to the revised Schedule M good manufacturing practice requirements, which now apply to smaller manufacturers as well following the extension granted to units with turnover of INR 250 crore or less.
Exhibitors listed for CPHI India include Dr Reddy’s Laboratories, Hetero Labs, Divi’s Laboratories, Akums Drugs, Jubilant Ingrevia, SMS Pharmaceuticals and Morepen Laboratories. PMEC India will feature ACG, Fette Compacting, Cadmach, GEA Process Engineering, IMA, Thermo Fisher Scientific and Shimadzu, among others. The shows are supported by Pharmexcil, the Indian Pharmaceutical Alliance, the Organisation of Pharmaceutical Producers of India, the Indian Drug Manufacturers’ Association and the Federation of Pharma Entrepreneurs.
